Patient-reported rating of gastrointestinal adverse effects during treatment of type 2 diabetes with the once-daily human GLP-1 analogue, liraglutide.

Glucagon-like peptide-1 [GLP-1], an incretin hormone secreted in response to food intake , has been demonstrated to reduce appetite, food intake and body weight and to slow gastric emptying. Its biological effects include a glucose-dependent insulinotropic effect on the pancreatic cells. The main adverse effects (AEs), which are gastrointestinal (GI), appear to be dose related and may result from GLP-1's inhibition of gastric emptying.Liraglutide is a human GLP-1 analogue designed for once-daily administration in patients with type 2 diabetes mellitus (T2DM). It lowers blood glucose by stimulating endogenous insulin secretion, decreasing blood glucagon levels and slowing gastric emptying. In a 14-week mono-therapy study in T2DM patients, liraglutide significantly improved glycaemic control, lowered body weight and was associated with improvements in beta-cell function and cardiovascular biomarkers [2-4]. Liraglutide is generally well tolerated. As with native GLP-1, the main AEs occur within the GI system [diarrhoea, constipation and nausea] and appear to be generally mild-moderate and transient in nature . The aim of this study was to evaluate GI AEs, for the first time, by using the Gastrointestinal System Rating Scale [GSRS] , a validated self-reporting instrument.

作 者：

Horowitz,M；Vilsboll,T；Zdravkovic,M；Hammer,M；Madsbad,S

刊 名：

Diabetes, obesity & metabolism 

年，卷(期)：

2008vol.10(no.7) 

分类号：

 

关键词：

Gastrointestinal  glucagon-like peptide 1  therapeutic aspects  Patients  病人

正文语种：

eng 

基金项目：